EU patent reforms better for all life sciences companies than those in US, say industry insiders

A survey of over 300 members of the pharma and biotech industries - including senior executives, researchers, academics, and investors – has revealed that while a healthy majority believes that European patent reform will benefit pharmaceutical and…

Get unlimited access to all IAM content